Cargando…
Gut Microbiota: A Promising Milestone in Enhancing the Efficacy of PD1/PD-L1 Blockade Therapy
In the past few decades, immunotherapy has emerged as one of the most promising strategies among current treatments of cancer. In particular, the field of PD1/PD-L1 inhibitors has been boosted, widely applied into clinical practice with potent therapeutic efficacy and remarkable survival benefits on...
Autores principales: | Zhou, Yuqing, Liu, Zhaoxia, Chen, Tingtao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8890472/ https://www.ncbi.nlm.nih.gov/pubmed/35252014 http://dx.doi.org/10.3389/fonc.2022.847350 |
Ejemplares similares
-
Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade
por: Tian, Tian, et al.
Publicado: (2021) -
The Research Progress of PD-1/PD-L1 Inhibitors Enhancing Radiotherapy Efficacy
por: Wen, Lu, et al.
Publicado: (2021) -
Does the gut microbiota play a key role in PD-1/PD-L1 blockade therapy?
por: Watanabe, Satoshi, et al.
Publicado: (2020) -
Down Regulation of c-FLIP(L) Enhance PD-1 Blockade Efficacy in B16 Melanoma
por: Wang, Yao, et al.
Publicado: (2019) -
A Novel Computational Framework for Predicting the Survival of Cancer Patients With PD-1/PD-L1 Checkpoint Blockade Therapy
por: Su, Xiaofan, et al.
Publicado: (2022)